BioLineRx and Hemispherian report new GLIX1 anti-tumor effect in GBM

BioLineRx (BLRX) and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, announced highly encouraging new preclinical data that further support the recently initiated Phase 1/2a clinical trial evaluating GLIX1 for the treatment of recurrent and progressive GBM and other high-grade gliomas. GBM remains one of the most aggressive and treatment-resistant cancers, urgently in need of breakthrough innovations and more effective treatment. In a comprehensive pre-clinical program, orally administered GLIX1 demonstrated robust anti-tumor activity in orthotopic cell-derived xenograft GBM models, as well as in a newly completed subcutaneous TMZ-resistant patient-derived xenograft GBM model. In the three orthotopic CDX studies, significant tumor growth inhibition and survival benefit were observed following treatment with GLIX1 across all doses tested, with greater benefit at higher dose levels. In these models, mice treated with TMZ also showed significantly decreased tumor volume and survival benefit. Most notably, in the subcutaneous PDX model, GLIX1 demonstrated a robust anti-tumor effect while TMZ showed no effect. BioLineRx and Hemispherian plan to present the data from these studies at one or more future medical conferences.